Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prurigo Nodularis: later-stage trial registry
5 of 15 indexed Prurigo Nodularis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 5 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Prurigo Nodularis: 15 US clinical trials tracked, 5 recruiting.
Prurigo Nodularis is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 5 of these trials.
Enrollment posture brief
Registry condition prurigo-nodularis
OPEN 5 | RECR 33% | LATE 8 | EARLY 5 | RANK #1140 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Prurigo Nodularis lists 5 open slots (33% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prurigo Nodularis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prurigo Nodularis is recruiting below its size-band peers.
5 of 15 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Prurigo Nodularis research.
Incyte Corporation accounts for 5 of 15 trials (33.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Prurigo Nodularis enrolment sits around 146 participants.
Median target enrolment is 146 among the 15 trials that report a genuine target (sentinel values excluded). 5 of those (33.3%) plan for fewer than 100 participants.
-
Prurigo Nodularis research is mostly interventional.
13 interventional and 2 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Galderma R&D
NCT06988618
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Incyte Corporation
NCT06516965
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Incyte Corporation
NCT06516952
Upadacitinib for Prurigo Nodularis
Psoriasis Treatment Center of Central New Jersey
NCT06773403
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
NCT06293053
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Galderma R&D
NCT04204616
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Amgen
NCT06527404
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Celldex Therapeutics
NCT06366750
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Sanofi
NCT05991323
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Galderma R&D
NCT04501679
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Incyte Corporation
NCT05764161
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Incyte Corporation
NCT05061693
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Trevi Therapeutics
NCT02174419
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Incyte Corporation
NCT06213831
Safety and Efficacy of CC-10004 for Prurigo Nodularis
University Hospitals Cleveland Medical Center
NCT00869089
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prurigo Nodularis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prurigo Nodularis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prurigo Nodularis page
15 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Prurigo Nodularis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Incyte Corporation sponsors the most Prurigo Nodularis trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prurigo Nodularis condition card totals 15 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.